Asset Details
Do you wish to reserve the book?
Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
Do you wish to request the book?
Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
2021
Overview
The objective of this study was to detect the Epstein–Barr virus (EBV) coinfection in coronavirus disease 2019 (COVID-19). In this retrospective single-center study, we included 67 COVID-19 patients with onset time within 2 weeks in Renmin Hospital of Wuhan University from January 9 to February 29, 2020. Patients were divided into EBV/SARS-CoV-2 coinfection group and SARS-CoV-2 infection alone group according to the serological results of EBV, and the characteristics differences between the two groups were compared. The median age was 37 years, with 35 (52.2%) females. Among these COVID-19 patients, thirty-seven (55.2%) patients were seropositive for EBV viral capsid antigen (VCA) IgM antibody. EBV/SARS-CoV-2 coinfection patients had a 3.09-fold risk of having a fever symptom than SARS-CoV-2 infection alone patients (95% CI 1.11–8.56; P = 0.03). C-reactive protein (CRP) (P = 0.02) and the aspartate aminotransferase (AST) (P = 0.04) in EBV/SARS-CoV-2 coinfection patients were higher than that in SARS-CoV-2 infection alone patients. EBV/SARS-CoV-2 coinfection patients had a higher portion of corticosteroid use than the SARS-CoV-2 infection alone patients (P = 0.03). We find a high incidence of EBV coinfection in COVID-19 patients. EBV/SARS-CoV-2 coinfection was associated with fever and increased inflammation. EBV reactivation may associated with the severity of COVID-19.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adrenal Cortex Hormones - therapeutic use
/ Adult
/ Aspartate Aminotransferases - blood
/ C-Reactive Protein - analysis
/ Capsid Proteins - immunology
/ COVID-19
/ Epstein-Barr Virus Infections - complications
/ Epstein-Barr Virus Infections - drug therapy
/ Epstein-Barr Virus Infections - pathology
/ Epstein-Barr Virus Infections - virology
/ Female
/ Fever
/ Herpesvirus 4, Human - immunology
/ Herpesvirus 4, Human - isolation & purification
/ Herpesvirus 4, Human - metabolism
/ Humanities and Social Sciences
/ Humans
/ Male
/ SARS-CoV-2 - isolation & purification
/ Science
